NL300139I1 - Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus. - Google Patents

Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.

Info

Publication number
NL300139I1
NL300139I1 NL300139C NL300139C NL300139I1 NL 300139 I1 NL300139 I1 NL 300139I1 NL 300139 C NL300139 C NL 300139C NL 300139 C NL300139 C NL 300139C NL 300139 I1 NL300139 I1 NL 300139I1
Authority
NL
Netherlands
Prior art keywords
recombinant pox
pox virus
expressing
dna
recombinant
Prior art date
Application number
NL300139C
Other languages
Dutch (nl)
Original Assignee
Health Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300139(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Health Res filed Critical Health Res
Publication of NL300139I1 publication Critical patent/NL300139I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300139C 1987-08-28 2003-11-25 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus. NL300139I1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9071187A 1987-08-28 1987-08-28
US11033587A 1987-10-20 1987-10-20
US18605488A 1988-04-25 1988-04-25
US23439088A 1988-08-23 1988-08-23

Publications (1)

Publication Number Publication Date
NL300139I1 true NL300139I1 (en) 2004-02-02

Family

ID=27492413

Family Applications (4)

Application Number Title Priority Date Filing Date
NL8820679A NL195051C (en) 1987-08-28 1988-08-24 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus, and method for expressing the DNA in a recombinant pox virus.
NL300130C NL300130I2 (en) 1987-08-28 2003-07-09 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.
NL300139C NL300139I1 (en) 1987-08-28 2003-11-25 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.
NL300138C NL300138I2 (en) 1987-08-28 2003-11-25 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NL8820679A NL195051C (en) 1987-08-28 1988-08-24 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus, and method for expressing the DNA in a recombinant pox virus.
NL300130C NL300130I2 (en) 1987-08-28 2003-07-09 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL300138C NL300138I2 (en) 1987-08-28 2003-11-25 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.

Country Status (17)

Country Link
JP (3) JP3348156B2 (en)
KR (1) KR970011149B1 (en)
AR (1) AR241939A1 (en)
AT (1) AT408549B (en)
AU (2) AU2427588A (en)
BE (1) BE1002134A5 (en)
CH (2) CH679934A5 (en)
DE (4) DE10399031I1 (en)
DK (1) DK175904B1 (en)
FR (1) FR2621487B1 (en)
GB (1) GB2217718B (en)
IL (1) IL87581A0 (en)
IT (1) IT1229484B (en)
LU (2) LU90951I2 (en)
NL (4) NL195051C (en)
NZ (1) NZ225970A (en)
WO (1) WO1989003429A1 (en)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
US5286639A (en) * 1987-09-16 1994-02-15 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE3813093A1 (en) * 1988-04-19 1989-11-09 Immuno Ag RECOMBINANT PLASMIDE, METHOD FOR PRODUCING A RECOMBINANT AVIPOX VIRUS, RECOMBINANT AVIPOX VIRUS, AND USE THEREOF
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
ES2061996T3 (en) * 1988-06-24 1994-12-16 British Tech Group NON-ESSENTIAL REGIONS OF AVIPOXVIRUSES.
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) * 1988-10-21 1990-04-21 Matthew M. Binns Fowlpox virus promoter
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
FR2668064B1 (en) 1990-10-23 1994-12-16 Transgene Sa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MALIGNANT TUMOR.
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
US5503834A (en) * 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
IE68404B1 (en) * 1990-11-20 1996-06-12 Virogenetics Corp Measles virus recombinant poxvirus vaccine
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5338679A (en) * 1991-01-08 1994-08-16 Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
CA2106464A1 (en) * 1991-03-20 1992-09-21 Enzo Paoletti Malaria recombinant poxvirus vaccine
DE69233080T2 (en) * 1991-06-14 2004-04-15 Connaught Technology Corp., Greenville RECOMBINANT HIV-SPECIFIC VACCINE FROM POXVIRU
JPH06509235A (en) * 1991-07-26 1994-10-20 ヴァイロジェネティクス　コーポレイション Infectious Bursal Disease Virus Recombinant Poxvirus Vaccine
EP1380651A2 (en) * 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
US5443831A (en) * 1991-10-29 1995-08-22 University Of Delaware Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6251403B1 (en) 1992-01-13 2001-06-26 Syntro Corporation Recombinant swinepox virus
US6127163A (en) * 1992-01-13 2000-10-03 Syntro Corporation Recombinant swinepox virus
US6328975B1 (en) 1992-01-13 2001-12-11 Syntro Corporation Recombinant swinepox virus
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US6497882B1 (en) 1992-01-13 2002-12-24 Syntro Corporation Recombinant swinepox virus
ES2236684T3 (en) * 1992-01-13 2005-07-16 Virogenetics Corporation VACCINE OF THE VACCINIA RECOMBINANT VACCINIA FROM THE VIRUS OF THE DISEASE OF MAREK.
JPH08501452A (en) * 1992-09-21 1996-02-20 ビアジーン，インコーポレイティド Recombinant retrovirus vector for FELV and / or FIV
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
AU727278B2 (en) * 1993-02-26 2000-12-07 Syntro Corporation Recombinant fowlpox viruses and uses thereof II
WO1994019015A1 (en) * 1993-02-26 1994-09-01 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
EP0954593A1 (en) 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
WO1999007869A1 (en) * 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (en) 1997-12-01 1999-06-22 Lintec Corp Cover tape for carrying chip body and sealing structure
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU5771500A (en) 1999-06-28 2001-01-31 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
PT1650221E (en) 2000-02-23 2012-09-05 Glaxosmithkline Biolog Sa Novel compounds
AR029540A1 (en) 2000-06-28 2003-07-02 Corixa Corp COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND THERAPY OF CA NCER DE PULMoN
US20030021766A1 (en) 2001-01-12 2003-01-30 Michael Vajdy Nucleic acid mucosal immunization
DE60209345T2 (en) * 2001-03-08 2006-08-03 Akzo Nobel N.V. LEPORIPOX-BASED VECTOR VACCINE
JP4499311B2 (en) * 2001-04-27 2010-07-07 シャープ株式会社 Broadcast receiving terminal
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1409694A4 (en) 2001-07-05 2006-02-08 Chiron Corp Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
JP5033303B2 (en) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Polynucleotides encoding polypeptides with antigenic type C HIV, polypeptides and uses thereof
EP2224012B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
HUE026376T2 (en) 2003-01-06 2016-05-30 Corixa Corp Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US20070073048A1 (en) 2003-05-15 2007-03-29 Ying Lian Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
KR101508563B1 (en) 2004-09-22 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. Immunogenic composition for use in vaccination against staphylococcei
ES2514316T3 (en) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
WO2007106536A2 (en) 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
ES2662030T3 (en) 2007-10-15 2018-04-05 Admedus Vaccines Pty Limited Construction system and uses for it
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP2384120B1 (en) 2009-01-05 2019-12-11 Epitogenesis Inc. Adjuvant compositions and methods of use
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
US8961989B2 (en) 2009-11-20 2015-02-24 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
BR112013032410A2 (en) 2011-06-24 2017-01-17 Epitogenesis Inc pharmaceutical compositions comprising a combination of selection vehicles, vitamins, tannins and flavonoids as antigen specific immunomodulators
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
CA3182572A1 (en) 2013-04-17 2014-10-23 Genzyme Corporation Use of an il17 inhibitor for treating and preventing macular degeneration
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
TWI687225B (en) 2014-02-06 2020-03-11 美商健臻公司 Compositions and methods for treating and preventing macular degeneration
JP7095990B2 (en) 2014-09-18 2022-07-05 シーダーズ－サイナイ メディカル センター Compositions and Methods for Treating Fibrosis
JP2018511655A (en) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Immunogenic compositions for use in vaccination against Bordetella
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
WO2016172479A1 (en) 2015-04-22 2016-10-27 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
EP3294755B1 (en) 2015-05-13 2023-08-23 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3313863B1 (en) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
AU2016367712B2 (en) 2015-12-09 2021-10-07 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US10917454B1 (en) 2019-08-01 2021-02-09 Rohde & Schwarz Gmbh & Co. Kg System and method for ATC voice quality assurance
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK489481A (en) * 1980-11-10 1982-05-11 Searle & Co PLASMID VECTOR AND METHOD OF PRODUCING THEREOF
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
WO1984002077A1 (en) * 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
FR2563434B1 (en) * 1984-04-25 1986-07-25 Transgene Sa Rabies vaccine and process for its preparation
WO1986000528A1 (en) * 1984-07-05 1986-01-30 Genex Corporation Cloned gene and method for making and using the same
DD235669A1 (en) * 1985-03-26 1986-05-14 Akad Wissenschaften Ddr METHOD FOR PRODUCING A BLV-CODED HUEL PROTEIN
US5032520A (en) * 1985-03-29 1991-07-16 National Research Development Corporation DNA sequences encoding infectious bronchitis virus spike protein
AU6170486A (en) * 1985-08-23 1987-02-26 Advanced Genetics Research Institute Defective viral vaccines
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
AU8075787A (en) * 1986-09-22 1988-04-07 Australian National University, The Recombinant poxviruses
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
AU605567B2 (en) * 1987-03-11 1991-01-17 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
GB8724885D0 (en) * 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
FR2632863B2 (en) * 1987-10-29 1990-08-31 Transgene Sa RECOMBINANT FOWLPOX VIRUS AND VACCINES DERIVED FROM SUCH VIRUSES
ES2061996T3 (en) * 1988-06-24 1994-12-16 British Tech Group NON-ESSENTIAL REGIONS OF AVIPOXVIRUSES.
JP3044062B2 (en) * 1989-03-08 2000-05-22 ヘルス・リサーチ・インク Recombinant poxvirus host selection system
EP0953648A3 (en) * 1990-09-25 2007-09-12 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line

Also Published As

Publication number Publication date
DK203689A (en) 1989-06-27
AR241939A1 (en) 1993-01-29
JP2002186494A (en) 2002-07-02
DE10399032I1 (en) 2004-01-29
WO1989003429A1 (en) 1989-04-20
JPH02500879A (en) 1990-03-29
DK175904B1 (en) 2005-06-06
AU690210B2 (en) 1998-04-23
IT8821772A0 (en) 1988-08-29
AT408549B (en) 2001-12-27
JP2002348255A (en) 2002-12-04
AU1628895A (en) 1995-08-17
DE10299049I1 (en) 2004-07-01
NL195051C (en) 2003-07-01
CH679933A5 (en) 1992-05-15
JP3348156B2 (en) 2002-11-20
IT1229484B (en) 1991-09-03
AU2427588A (en) 1989-05-02
NL300130I1 (en) 2003-09-01
ATA900788A (en) 1995-05-15
DE3890874C5 (en) 2005-10-20
BE1002134A5 (en) 1990-07-24
KR890701757A (en) 1989-12-21
NL300138I1 (en) 2004-02-02
FR2621487B1 (en) 1991-10-18
JP3826055B2 (en) 2006-09-27
NL300130I2 (en) 2005-11-01
DE3890874C2 (en) 2003-03-13
DE10399031I1 (en) 2004-01-29
CH679934A5 (en) 1992-05-15
KR970011149B1 (en) 1997-07-07
LU91039I2 (en) 2003-11-05
GB2217718B (en) 1992-05-20
NL300138I2 (en) 2004-03-01
NL8820679A (en) 1989-07-03
GB8908921D0 (en) 1989-08-02
LU90951I2 (en) 2003-01-15
NZ225970A (en) 1991-01-29
DK203689D0 (en) 1989-04-27
GB2217718A (en) 1989-11-01
FR2621487A1 (en) 1989-04-14
IL87581A0 (en) 1989-01-31

Similar Documents

Publication Publication Date Title
NL300130I2 (en) Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.
NL192275B (en) Protein from the AIDS virus.
NL192880B (en) Nucleic acid encoding the surface antigen of a Hepatitis B virus, peptide encoding it, vector containing the nucleic acid, hybrid protein encoding the nucleic acid inserted into the vector, and vaccine containing the hybrid protein.
NL193884B (en) Vibration type transducer and method for its manufacture.
NO881064L (en) PROCEDURE FOR DETERMINING NUCLEIC ACIDS BY HYBRIDIZATION TECHNIQUE, REAGENT COMBINATION AND TEST PACKAGE FOR CARRYING OUT THE PROCEDURE.
EP0179139A4 (en) Leukemia-associated virus immunogen, vaccine and assay.
GR3034708T3 (en) Retrovirus of the type HIV-2 capable of inducing AIDS, and the antigenic and nucleic acid components thereof.
DE3678857D1 (en) CERAMIC COMPOSITE BODY AND METHOD FOR THE PRODUCTION THEREOF.
IT1215511B (en) MOLDS FOR MOLDING, AND METHOD OF PREPARATION OF THE MOLDING CONDITIONS FOR SAID.
NL930133I2 (en) Vaccine against hepatitis B virus, method and transformed eukaryotic cells and the preparation of that vaccine.
NO891818D0 (en) T4 RECEPTOR PROTEIN, RELATED DNA SEQUENCES AND PREPARATION thereof.
DE3875040D1 (en) CERAMIC / METAL COMPOSITE.
DE3774313D1 (en) HIGH-STRENGTH CERAMIC HONEYCOMB STRUCTURE.
NL7905375A (en) PROSTANOIDS, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL PREPARATIONS BASED ON THAT
NO871025L (en) POLYPEPTID, DNA AND PROCEDURE FOR PREPARING THEREOF.
NL191934C (en) Method and device for the production of glazed ceramic bodies.
DE3785702D1 (en) METHOD FOR HANDLING LOADS AND MEANS FOR CARRYING OUT THE SAME.
DE3868867D1 (en) HIGH-STRENGTH, HEAT-RESISTANT ALUMINUM ALLOYS.
DE3788807D1 (en) FUSION PROTEINS AND PARTICLES.
IT7927399A0 (en) CHORIONIC GONADOTROPIN PREPARATIONS AND METHODS FOR USING THEM.
DE3680546D1 (en) PROCESS FOR REDUCING ALDEHYDES AND KETONES.
DE3888308D1 (en) Heat-resistant, sintered aluminum alloy and process for its production.
EP0311228A3 (en) Recombinant polypeptides and their uses, including assay for aids virus
DE3872189D1 (en) HANDLING VEHICLE FOR THE MANIPULATION OF HEAVY, BULKY LOADS.
DE60026666D1 (en) Induction of antigen-specific T cells by interferon